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Abstract
Background: Medicinal cannabis has received increased research attention over recent years due to loosening
global regulatory changes. Medicinal cannabis has been reported to have potential efficacy in reducing pain,
muscle spasticity, chemotherapy-induced nausea and vomiting, and intractable childhood epilepsy. Yet its potential
application in the field of psychiatry is lesser known.
Methods: The first clinically-focused systematic review on the emerging medical application of cannabis across all
major psychiatric disorders was conducted. Current evidence regarding whole plant formulations and plant-derived
cannabinoid isolates in mood, anxiety, sleep, psychotic disorders and attention deficit/hyperactivity disorder (ADHD)
is discussed; while also detailing clinical prescription considerations (including pharmacogenomics), occupational
and public health elements, and future research recommendations. The systematic review of the literature was
conducted during 2019, assessing the data from all case studies and clinical trials involving medicinal cannabis or
plant-derived isolates for all major psychiatric disorders (neurological conditions and pain were omitted).
Results: The present evidence in the emerging field of cannabinoid therapeutics in psychiatry is nascent, and
thereby it is currently premature to recommend cannabinoid-based interventions. Isolated positive studies have,
however, revealed tentative support for cannabinoids (namely cannabidiol; CBD) for reducing social anxiety; with
mixed (mainly positive) evidence for adjunctive use in schizophrenia. Case studies suggest that medicinal cannabis
may be beneficial for improving sleep and post-traumatic stress disorder, however evidence is currently weak.
Preliminary research findings indicate no benefit for depression from high delta-9 tetrahydrocannabinol (THC)
therapeutics, or for CBD in mania. One isolated study indicates some potential efficacy for an oral cannabinoid/
terpene combination in ADHD. Clinical prescriptive consideration involves caution in the use of high-THC
formulations (avoidance in youth, and in people with anxiety or psychotic disorders), gradual titration, regular
assessment, and caution in cardiovascular and respiratory disorders, pregnancy and breast-feeding.
Conclusions: There is currently encouraging, albeit embryonic, evidence for medicinal cannabis in the treatment of
a range of psychiatric disorders. Supportive findings are emerging for some key isolates, however, clinicians need to
be mindful of a range of prescriptive and occupational safety considerations, especially if initiating higher dose THC
formulas.
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Introduction
The Cannabaceae family is a comparatively small family
of flowering plants encompassing 11 genera and ap-
proximately 170 different species, a small number of
which elicit a range of varying psychoactive effects [1].
Several medical applications have been studied over the
past decades, with the National Academies of Sciences,
Engineering and Medicine (NASEM) recently holding
the position that cannabis and cannabinoids demon-
strate conclusive or substantial evidence for chronic pain
in adults, chemotherapy-induced nausea and vomiting
and spasticity in multiple sclerosis, with limited evidence
for use in increasing appetite in HIV/AIDS patients and
improving symptoms of post-traumatic stress disorder
(PTSD) [2].
While there is increasing psychiatric interest (and de-
bate) regarding the potential mental health applications
(in concert with concerns over the potential for trigger-
ing latent psychosis), historical evidence for the use of
cannabis in mental health conditions is remarkably an-
cient. For instance, the Shen-nung Pen-tsao Ching (Div-
ine Husbandman’s Materia Medica) described its benefit
as an anti-senility agent [3, 4], while in the Assyrian cul-
ture, cannabis was indicated as a drug for grief and sor-
row [5, 6]. Sections of the Indian Atharva Veda (1500
BCE) suggest bhanga (Cannabis) exerted anxiolytic ef-
fects [5, 7], while in 1563, Da Orta [8] described canna-
bis as allaying anxiety and engendering laughter. With
respect to modern use, contemporary consumers of can-
nabis report (as assessed via meta-analysis of patient
usage data) that pain (64%), anxiety (50%), and depres-
sion/mood (34%) are the most common reasons [9].
Increasing scientific research, conducted over recent
years, has seen the regulatory pendulum swinging away
from the United Nations Single Convention on Narcotic
Drugs in 1961 (which recommends enforcement of canna-
bis use as illegal) [10], towards consideration of its poten-
tial use in medical conditions. Recent scientific evidence
ascribes anxiolytic, neuroprotective, antioxidant, anti-
inflammatory, antidepressant, anti-psychotic and hypnotic
pharmacological actions due to several phytochemicals
commonly found in the cannabis genus [11, 12].
While Δ9-tetrahydrocannabinol (THC) is considered the
main psychoactive constituent, other cannabinoids have
also revealed less potent psychotropic effects. These include
cannabidiol (CBD) [13], Δ8-tetrahydrocannabinol [14], and
other less-studied cannabinoids including cannabinol
(CBN) and Δ8 tetrahydrocannabivarin (THCV) [15]. Fur-
ther, many other constituents such as the terpenes (i.e.
volatile organic compounds found mainly as essential oils
in many plants), also provoke a range of biological effects,
and produce the characteristic aroma of the plant [16]. The
hundreds of cannabis chemovars or varieties (commonly
referred to as strains) developed over millennia have unique
and complex constituent profiles, of which each may pro-
vide targeted therapeutic usage due to the unique synergis-
tic combination of plant chemicals. Some pharmaceutical
preparations have attempted to isolate the key constituents
(there are over 140 phytocannabinoids [17]) to provide
standardised formulas that may harness this ‘entourage ef-
fect’ [16, 18], while being able to provide batch-to-batch as-
surance of the medicine.
While other reviews have covered cannabis’ use in a
range of conditions (cf. Whiting et al. 2015 [10] for a
general review of evidence for medicinal cannabis), none
to date have provided both a systematic and ‘clinically-
focused’ review on psychiatric disorders. As the focus
was on emerging data for the use of mental health disor-
ders, we omitted addiction and neurological disorders,
which have been extensively covered elsewhere [10, 19],
cf. pain [20–22], cf. epilepsy [23, 24], cf. movement dis-
orders [25]. A further motive for this paper focusing
solely on psychiatric disorders, concerns cannabis users
noting that self-reported anxiety, insomnia, and depres-
sion symptoms are amongst the most common reasons
for usage [26].
Thus, the primary purpose of this paper is to provide a
systematic review of the current state of evidence in the
emerging field of cannabinoid therapies for psychiatric
disorders (PTSD, generalised anxiety disorder, social
anxiety, insomnia, psychotic disorders, and attention-
deficit hyperactivity disorder: ADHD). In addition, this
review provides clinical prescriptive guidelines and con-
sideration of both safety and occupational public health
issues. We also provide discussion on considerations for
future research in the field. Our intention was to provide
a review of the extant literature to inform a discussion
with clinical context and appropriate recommendations.
Methods
Due to the field still being in its infancy, a broad inclu-
sion criteria was applied to the available data. The pur-
pose was to locate human studies involving whole
cannabis plant medicines and cannabis-derived isolates
(singularly or in combinations) for the treatment of
major psychiatric disorders or mental health symptoms.
Synthetic cannabinoid analogues (e.g. nabilone) and
THC isomers (e.g. dronabinol) were omitted as these fall
under the auspices of a pharmaceutical-focused review
(as these are classified as pharmaceutical ‘drugs’).
Major electronic databases including OVID MEDLINE,
Cochrane Central Register of Controlled Trials, Health
Technology Assessment Database, Allied and Comple-
mentary Medicine and PsychINFO were accessed for data
up to July 2019. Initially, data were sought for meta-
analytic or systematic review level epidemiological evi-
dence (as there is sufficient data available) on the cross-
sectional or longitudinal association of cannabis use and
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individual psychiatric disorders or symptoms. This was
undertaken to assess any deleterious relationship between
cannabis and psychiatric disorders. We then specifically
sought any literature involving interventional human trials
and observational studies, including case studies (due to
deficient randomised controlled trials [RCTs] in this
emerging area). We included studies with any sample size
or age or gender, which used either inhalant, oral, or
transdermal administration of medicinal cannabis or
cannabis-derived isolates. All studies in English were
assessed for inclusion (see supplementary data for the
PRISMA flow chart for the number of human clinical tri-
als or case studies excluded/included). The results are pre-
sented to firstly cover the major current epidemiological
evidence, and then next all available clinical trial or case
study data.
The following search terms were used to locate human
studies or case report publications:
TITLE: cannab* OR THC OR tetrahydrocannabinol OR
canab*
AND
TITLE: depression or depressive or mental illness* or
mental disorder* or mental health or mood disorder*
or affective disorder* or anxi* or panic disorder or
obsessive compulsive or adhd or attention deficit or
phobi* or bipolar or psychiat* or psychological or
psychosis or psychotic or schizophr* severe mental* or
serious mental* or antidepress* or antipsychotic* or
post traumatic* or personality disorder* or stress
In summation, 481 articles were located, which was re-
duced to 310 after duplicates were removed. Of these,
13 studies fitted the eligibility criteria as clinical studies
of cannabis-based treatments for symptoms of psychi-
atric disorders. The full search and screening process is
displayed in the supplementary data. There were insuffi-
cient homogenous studies to perform a meta-analysis.
Affective disorders
Anxiety
The endocannabinoid system has been found to be a
modulator of anxiety and mood, with recent data showing
that cannabinoids or substances which target this system
may interact with specific brain regions, including the
medial prefrontal cortex, amygdaloid complex, bed nu-
cleus of stria terminalis, and hippocampus [27]. Inter-
action with the CB1 receptor has a modulating effect on
GABAergic and Glutamatergic transmission [28], while
also influencing the hypothalamic pituitary adrenal (HPA)
axis, immune system activation, and neuroplastic mecha-
nisms. In respect to specific psychotropic mechanisms
of action, the anxiolytic (and antidepressant effects)
may also in part be mediated via CBD’s serotonergic
effects via 5-HT1A receptor activation [29], and
THC’s CB1 receptor agonism [30, 31]. It is worth
noting that studies have demonstrated that CBD may
partially inhibit the psychoactive effects of THC, with
CBD and THC having demonstrated differing symp-
tomatic and behavioural effects on regional brain
function [32–35].
As in the case of certain other psychiatric symptoms
and disorders, epidemiological evidence indicates that
there is a relationship between cannabis use and anxiety
symptom levels. This association (assessed by Kelzior and
colleagues [36] via meta-analysis of 31 studies) has to date
only been found to be weak, and based largely on cross-
sectional data. Thus, it may be that those with anxiety seek
cannabis treatment, rather than a causal effect occurring
from cannabis use. Longitudinal data is also not convin-
cing due to the bias of one study with a large odds ratio
included in their meta-analysis. However, a stronger posi-
tive association was revealed between anxiety and canna-
bis use disorder. Other longitudinal data involving the
USA-based National Epidemiologic survey on Alcohol
and Related Conditions [37] confirms there is no obvious
causal inference. The study included individuals with a
diagnosis of any anxiety disorder during the initial 4-year
data collection period, comparing cannabis nonusers to
users, and also individuals with cannabis use disorder at a
later time point on a range of psychosocial measures. Re-
sults revealed that, when controlling for baseline con-
founders, no significant relationship was found with
cannabis use and a greater frequency of anxiety.
While to date no human trials could be located for treat-
ment of Generalised Anxiety Disorder using whole cannabis
plant extracts or combined isolates, there was one study
identified testing CBD (Table 1) for Social Anxiety Disorder.
One small preliminary double-blind RCT compared the ef-
fects of a simulated public speaking test on treatment-naïve
patients with social anxiety (n= 24) versus healthy control
participants (n= 12) [38]. Each group received a single acute
oral dose of CBD (600mg) 1.5 h before the test, or matching
placebo. Results revealed that pre-treatment with CBD sig-
nificantly reduced anxiety, cognitive impairment and discom-
fort in the social anxiety group’s speech performance, and
significantly decreased hyper-alertness in their anticipatory
speech compared to the placebo group (which presented
higher anxiety, cognitive impairment, discomfort, and higher
alertness levels). Neuroimaging research has also revealed
that in individuals diagnosed with social anxiety, cerebral
blood flow may be altered via CBD. One study employed
fMRI in 10 treatment-naïve patients with social anxiety who
were given 400mg of oral CBD or placebo in a double-
blinded crossover manner. Relative to placebo, 400mg of
CBD was associated with significantly decreased subjective
anxiety, with blood flow being modulated in the left parahip-
pocampal gyrus, hippocampus, and inferior temporal gyrus,
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Table 1 Medicinal cannabis trials in mental disorders
Mental
Disorder#
Cannabinoid(s)
Studied
Methodology Results Clinical Comment
Social Anxiety
Bergamaschi
[38]
CBD (600 mg) 24 treatment-naïve patients with Social
Anxiety were blindly allocated to
receive CBD or placebo 1.5 h before a
simulated public speaking test. 12
unmedicated healthy controls also
completed the test. Self-reports on the
Visual Analogue Mood Scale, and
Negative Self-Statement scale, and
physiological measures were taken
at six time points during the test
Pre-test CBD administration in
Social Anxiety patients versus
placebo, resulted in significantly
reduced anxiety, cognitive
impairment and discomfort in
speech performance, and
significantly decreased hyper-
alertness in anticipatory speech.
CBD and control groups however
did not differ, reflecting similar res
ponse profiles during the public
speaking test
The initial positive studies
suggest that CBD may be a
beneficial safe option (a larger
confirmatory study needed)
Crippa [39] CBD (400 mg) Compared regional cerebral blood flow
activity in 10 treatment-naïve patients
with SAD who were given CBD or
placebo, in a double-blinded crossover
manner
CBD compared to placebo, resulted
in significantly lower subjective
anxiety, and modulated blood flow
in the left parahippocampal gyrus,
hippocampus, and inferior temporal
gyrus, and right posterior cingulate
gyrus
PTSD
Greer [54] Cannabis (not
defined)
Analysed retrospectively collected
CAPS data from 80 patients with PTSD
Patients reported > 75% decrease in
CAPS scores when they were using
cannabis compared to periods
when they were not
No firm evidence yet, however
initial case analyses suggest this
application may be of benefit to
manage PTSD symptoms,
reduce anxiety, and improve
sleepElms [53] CBD (capsule or
spray; mean
dosage at week-
8 of 49 mg)
Open label retrospective case study
data from 11 adult patients with PTSD.
Data assessed over 8 weeks
Mean PTSD symptoms on the PCL-5
reduced by 28%. Actual statistical
data analysis not conducted
Depression
Portenoy
[60]
Nabiximols: THC
(2.7 mg) and
CBD (2.5 mg)
263 patients with advanced cancer and
opioid-refractory pain were randomly
allocated to receive placebo or nabixi
mols daily at low (1–4 sprays), medium
(6–10 sprays) or high (11–16 sprays)
doses, for 5 weeks. Pre/post-measures
included average pain, worst pain,
sleep disruption, quality of life and
mood
Reports of pain relief were
significantly greater for nabiximols
than placebo overall, especially in
the low- and medium-dose groups.
There were no other significant
group differences. Adverse events
were dose-related with only the
high-dose group reporting a
decrease in mood
No evidence for use in depres
sion, however higher doses of
THC-predominant medicines
may in fact lower mood
Insomnia
Shannon
[69]
CBD capsules
(25 mg) + liquid
(6–25 mg)
Patient (10 y.o. girl with prior early
childhood trauma) was prescribed fish
oil (750 mg daily) + 1 CBD oil capsule
daily for 5 months. CBD liquid (12–24
mg) was added to the regime for 1
month and reduced to 6–12mg p.r.n
(or ‘when needed’). Sleep assessed
monthly via SDSC
SDSC scores decreased over the
5-month period, indicating an in
crease in sleep quality and quantity
Only case study and secondary
outcome evidence at present.
Encouraging as a potential use
pending controlled studies,
however next-day effects need
to be assessed in terms of
somnolence and cognitive
functioning
Johnson
[71]
Nabiximols: THC
(2.7 mg) and
CBD (2.5 mg) OR
THC only (2.7
mg)
43 patients, with advanced cancer and
opioid-refractory pain, self-administered
daily nabiximols or THC-only sprays for
5 weeks. Safety, tolerability, pain and
quality of life were assessed
Across groups, pain decreased at
every visit, and showed pre−/post
improvement with insomnia and
fatigue
Shannon
[70]
CBD capsules
(mainly 25 mg/
day)
A retrospective case series of 72 adults
given CBD for anxiety and sleep
complaints at a psychiatric clinic, as an
adjunct to usual treatment. Assessed
monthly over 12 weeks
Anxiety scores on the HAMA
decreased within the first month in
79% of the sample and remained
decreased during the study
duration. PSQI sleep score improved
within the first month in 67%, but
fluctuated over time. Data appeared to
not be statistically significant for the
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and the right posterior cingulate gyrus [39]. This suggests
that CBD’s activity may occur via interaction with the limbic
and paralimbic brain areas.
Due to the small sample sizes, the above data needs to
be considered with caution. Further, appropriate and con-
sidered treatment of anxiety disorders with cannabinoid
therapies is crucial due to the complex relationship with
substance use disorders, often requiring a more complex
biopsychosocial approach [40]. With this context in mind,
CBD (being a non-intoxicant compared to THC) may be a
more preferable option, having also shown anxiolytic ef-
fects in preclinical studies [41].
In respect to planned or ongoing research, one study
in Colorado USA has just commenced and is exploring
Table 1 Medicinal cannabis trials in mental disorders (Continued)
Mental
Disorder#
Cannabinoid(s)
Studied
Methodology Results Clinical Comment
group presenting with a
primary complaint of anxiety (those
with sleep disturbance fared better)
Schizophrenia
Leweke [99] CBD (600–800
mg)
42 individuals with schizophrenia were
randomly assigned to receive 600–800
mg of CBD or amisulpride over 4
weeks. The PANSS and BPRS were
administered every 14 days. Blood was
also collected
Both treatments were effective in
reducing PANSS and BPRS scores at
each time point. CBD was tolerated
better, with fewer side effects
reported. Anandamide levels were
higher in the CBD group post-
treatment
Avoid any use of high THC in
youth. 600 mg–1200 mg of CBD
per day may be effective as an
adjunct for +ve and -ve
symptoms
McGuire
[101]
CBD (1000mg) 88 antipsychotic-treated patients with
schizophrenia were randomly given
placebo or CBD alongside existing
medication for 6 weeks. Pre/post-trial
measures included the PANSS, Brief As
sessment of Cognition in Schizophre
nia, Global Assessment of Functioning,
Clinical Global Impressions of Improve
ment and Severity scales.
The CBD group reported lower
positive symptom scores, and were
more likely to be rated as improved
and less severely ill than the
placebo group. The CBD group also
showed improvements in the
cognitive domain of motor speed
compared to placebo. CBD was
tolerated well with similar adverse
event rates reported between the
groups
Boggs [102] CBD (600 mg) 36 individuals with schizophrenia were
randomised to receive CBD or placebo
adjunctively to current antipsychotic
medication for 6 weeks. PANSS and
MCCB were assessed pre/post-trial
Both groups showed improvement
on PANSS scores and only
the placebo group improved on the
MCCB. Similar side effects were
noted between the groups, with
more sedation evident in the CBD
group
Bipolar Disorder
Zuardi
[105]
CBD (600–1200
mg)
Two patients with bipolar I disorder
were administered CBD for 30 days
with 5 days of placebo pre/post-trial.
Patients were assessed on the YMRS
and BPRS every 7 days
One patient showed improvements
in YMRS and BPRS scores while on
CBD plus olanzapine but no
additional improvement during
CBD monotherapy. The second
patient had no symptom
improvement with any dose of
CBD. Both tolerated CBD well with
no side effects reported.
Not presently recommended.
CBD appears not to be effective
in attenuating mania
ADHD
Cooper
[108]
Nabiximols: THC
(2.7 mg) and
CBD (2.5 mg)
30 adults with ADHD were randomly
prescribed nabiximols or placebo for 6
weeks. A participant’s optimal dose was
decided at day 14. The QBT assessed
cognitive performance and activity
level (head movements), Conners Adult
ADHD Rating Scale rated ADHD
symptoms, and self-reports to examine
emotional lability
The nabiximols group showed an
improvement in QBT scores that
approached significance. Nominally
significant improvements in ADHD
symptoms were also found for the
nabiximols group compared to
placebo
Potentially may be effective in
managing some ADHD
symptoms however more
research is needed. Lower THC
formulas alleviate concerns
about cognitive impairment
# First Author; THC Tetrahydrocannabinol, CBD Cannabidiol, QBT Quantitative Behavioural Test, PANSS Positive and Negative Syndrome Scale, MCCB MATRICS
Consensus Cognitive Battery, HAMA Hamilton Anxiety rating Scale, PSQI Pittsburgh Sleep Quality Index, YMRS Young Mania Rating Scale, BPRS Brief Psychiatric
Rating Scale, SDSC Sleep Disturbance Scale for Children, CAPS Clinician Administered Posttraumatic Scale; PLC-5 = PTSD checklist for DSM-5
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the anxiolytic effects of vaporised or ingested THC/CBD
in differing ratios (1:0, 1:1, 0:1) in people with mild-
moderate anxiety [42]. Another study is assessing the
effect of CBD on reducing symptoms of anxiety disorders
in a youth cohort (12–25 years old). The Australian-based
study is a 12-week open-label pilot, which aims to see if
200mg–800mg of oral CBD (titrated depending on age,
tolerability, and efficacy) is safe and effective for a youth
population [43].
Post-traumatic stress disorder (PTSD)
Whole plant cannabis use for the management of PTSD
symptoms has been identified in usage analyses [44], and
in particular in returned armed services veterans [45].
The proposed neurobiological mechanisms by which
medicinal cannabis may assist with PTSD are varied and
mostly derived from animal research. There are high
concentrations of endocannabinoid receptors in the pre-
frontal cortex, amygdala and hippocampus [46], having a
role in fear acquisition and extinction [47]. There is
strong evidence revealing that a disruption of the endo-
cannabinoid system impairs fear extinction in CB1
knockout mice, suggestive of a critical role of CB1 recep-
tors (and thereby potentially THC) being related to the
extinction of fear [48–50].
One survey involving a convenience sample of 170
patients via a medical cannabis dispensary in California
evaluated a range of health elements, the frequency of
cannabis use, and general mental health [51]. Results re-
vealed that those with high PTSD scores (assessed via
The PTSD Checklist-Civilian Version) were more likely
to use cannabis to assist with mental health coping, in
addition to improving sleep, when compared with those
with low PTSD scores. In particular, cannabis use fre-
quency was greater among those with high PTSD scores
who often used this for improving sleep. While there is
increased use of cannabis in those with PTSD, there is
currently no firmly supportive epidemiological data. A
cross-sectional case control study of veterans showed
that regular users do not have lower PTSD symptoms
than non-users [52].
A recent open label retrospective analysis of case study
data from 11 adults with PTSD assessed the patients
over 8 weeks of CBD treatment (capsule or spray; mean
dosage at week-8 of 49 mg) [53]. Results revealed that a
reduction in mean PTSD symptoms occurred in 28% of
the sample, as assessed on the PTSD checklist for DSM-
5 (PCL-5). Statistical data analysis was not conducted,
however, and thereby it is not possible to draw firm con-
clusions. Another retrospective study analysing PTSD
symptoms collected during 80 psychiatric evaluations of
patients applying to the New Mexico Medical Cannabis
Program during 2009 to 2011 [54], revealed more sup-
portive findings. The data identified a greater than 75%
reduction in Clinician Administered Posttraumatic Scale
for DSM-IV (CAPS) symptom scores when patients with
PTSD were using cannabis compared to when they were
not. While this study had a small sample, and is a retro-
spective analysis that has some methodological weak-
nesses, a 75% reduction on the CAPS is a compelling
result, and has spurred recent RCTs which are currently
in recruitment [55, 56].
Depression
Phytocannabinoids and terpenes have a potential appli-
cation for modulation of the endocannabinoid system
and the 5HT1A receptor to provide an antidepressant
effect [16]. No RCTs to date have been conducted on
the primary outcome of depression. Three studies asses-
sing oral-administered nabiximols (i.e. botanically de-
rived preparation containing standardised levels of THC,
CBD, terpenes and flavonoids from cannabis) for other
conditions (multiple sclerosis and cannabis withdrawal)
found no significant effect on the secondary outcome of
depression [57–59]. It is worth noting that one study in-
volving cancer patients using nabiximols showed a sig-
nificant reduction in mood occurred for those who used
the highest dose (11–16 sprays per day) compared to the
placebo [60]. Further, some epidemiological evidence
has revealed a greater level of depressive symptoms in
heavy cannabis users compared to light-users and non-
users [61]. Due to this, higher dose THC should be
avoided in people with major depressive disorder
(MDD) or low mood. However, a cross-sectional survey
on patterns of use and perceived efficacy suggested that
in over 1429 participants identified as medical cannabis
users, over 50% reported using medicinal cannabis spe-
cifically for depression [62].
Insomnia
Anecdotal survey evidence abounds for the soporific ef-
fect of cannabis, with sufferers of a range of conditions
including pain, anxiety and PTSD reporting that it as-
sists in the management of insomnia [51, 63–68]. While
this may commonly take the form of whole plant canna-
bis being administered via vaporised inhalation, isolated
CBD may also be of benefit. An example case study de-
tailed in the literature concerns a 10-year-old girl with
prior early childhood trauma [69]. A trial of oral CBD
oil (25 mg) resulted in a decrease in this patient’s anx-
iety, and improvement in the quality and quantity of her
sleep. A more substantial retrospective case series of 72
adults given CBD for anxiety and sleep complaints at a
psychiatric clinic (as an adjunct to usual treatment)
assessed patient data monthly over 12 weeks [70].
Anxiety scores on the Hamilton Anxiety rating Scale
(HAMA) decreased within the first month in 79% of the
sample and remained low during the study duration.
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The Pittsburgh Sleep Quality Index score also improved
within the first month in 67% of the sample, but fluctu-
ated over time. It should be noted that the data were not
analysed for statistical significance, and it appeared that
the sub-sample presenting primarily for anxiety treat-
ment did not fare as well as the cohort presenting pri-
marily with sleep issues.
A study by Johnson et al. [71] tested the long-term
safety and tolerability of a THC/CBD spray and a THC
spray in relieving pain in patients with advanced cancer.
A total of 43 patients were continued on a previous
three-arm RCT involving an open label administration
of a self-titrated THC/CBD spray (n = 39) or THC spray
(n = 4) (2.7 mg) assessed over a 5-week period. While
results revealed a consistent reduction in perceived
pain, participants also reported a decrease in their in-
somnia, which also reflected less fatigue. Cannabinoids
may have a dual effect of lessening pain (which makes
it easier to sleep), in addition to their direct soporific
and anxiolytic effects being mediated in part via seroto-
nergic activity.
As detailed above, the evidence for this use is currently
very weak, and to date no RCTs were located in the lit-
erature specifically assessing cannabinoid isolates or
whole plant formulas. As of late 2018, there is however,
a clinical trial taking place in Australia assessing canna-
binoid treatment in chronic insomnia [72]. The study,
based in Western Australia, is aiming to enrol 24 partici-
pants aged (25–70 years) who have insomnia (defined as
difficulty initiating or maintaining sleep for 3 or more
nights per week for at least 3 months). The intervention
involves an oral MC extract (ZTL-101) or placebo given
in a cross-over manner for a study period of approxi-
mately 2 months. Participants will be assessed via the
clinically-validated insomnia scales, an actigraph watch,
and will be assessed in a sleep centre after 2-weeks.
Psychotic disorders
Schizophrenia
Consistent evidence has shown that there is a relation-
ship between schizophrenia and cannabis use [73–75].
Heavy cannabis use may proceed to a diagnosis of the
disorder, however, increased use may also result from
‘self-medication’. Cannabis use is cross-sectionally asso-
ciated with more severe symptoms of psychosis in young
people who do not meet the threshold for schizophrenia,
and appears to be one high-risk component for the tu-
mescence of the disorder [76]. More importantly, there
is also longitudinal data to support a causal relationship
[77–79]. A 2016 meta-analysis showed that while general
lifetime use is not cross-sectionally associated with in-
creased risk of psychosis, there is a robust relationship
demonstrated in recent or current use in ultra-high-risk
(UHR) adolescents with a DSM-diagnosed cannabis use
disorder [80]. A recent prominent study has corrobo-
rated this finding. Data from 11 sites across Europe and
Brazil involving patients with first-episode psychosis ver-
sus population controls, revealed that daily cannabis use
was associated with increased odds of a psychotic dis-
order occurring compared with never-users, with nearly
five-times increased odds for daily use of high-potency
THC types of cannabis [81]. Several academics [82–86]
have disputed these findings and comment that while
there is a relationship, cannabis use is not causally re-
lated to increased psychosis risk (potentially due to a
range of confounders e.g. correlated genetic liabilities or
indirect and bidirectional processes). However, di Forti
and colleagues (the study authors) [87] maintain that the
data does indeed support this causal association, and
that other research has flawed elements (e.g. previous
Mendelian Randomisation studies using imprecise mea-
surements of cannabis use).
It is of note that schizophrenia risk alleles are linked
to cannabis use in a general population [78]. Regardless,
the transition rates from a general population of canna-
bis users to schizophrenia is very low and can be consid-
ered to be part of a constellation of various potential
gene-environment interactions. Several key genes have
been implicated as potentially modulating the risk of de-
veloping schizophrenia after early cannabis use: BDNF,
CNR1, COMT, AKT1, and DRD2 genes [88, 89]. There
is also a likely increased susceptibility when a combin-
ation of these at-risk alleles from these single nucleotide
polymorphisms (SNPs) are combined with childhood
trauma [90, 91].
The apprehension regarding the promotion of psych-
otic symptoms are primarily based on the THC con-
stituent of cannabis, a CB1 receptor agonist, which is
the primary psychoactive phytochemical. This effect
has been shown to be more prominent in users of high-
THC cannabis, or in chronic heavy users [92]. Thus,
THC should be avoided in people with or at risk of
schizophrenia. Exposure to THC increases extracellular
dopamine and glutamate and decreases GABA concen-
trations in the prefrontal cortex [93]. A recent double-
blind crossover RCT investigated whether altered
striatal glutamate (measured via proton magnetic res-
onance spectroscopy) was a mediating biomarker from
intravenously administered THC in 16 healthy partici-
pants [94]. Results revealed that that an increase in
striatal glutamate levels may underlie acute cannabis-
induced psychosis, while lower baseline levels may
provide a valid biomarker of greater sensitivity to its
acute psychotomimetic effects.
The psychotropic effects of THC may mimic the pres-
entation of psychotic symptoms, including paranoia, sen-
sory alteration, euphoria, and hallucinations [95]. In
laboratory-based research, people with schizophrenia
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appear to be even more sensitive to the psychosis-
inducing effects of THC than healthy controls [96]. In
contrast to THC, as mentioned in the introduction, CBD
may in fact provide an opposing effect to THC albeit
more research into this mechanism is required.
Additional effects include the inhibition of anandamide
breakdown via fatty acid amide hydrolase (FAAH) block-
ing effects, and anti-inflammatory effects [97, 98].
CBD is well-tolerated with minimal deleterious psy-
choactive effects (although some psychological effects
are evident due to modulation of the 5HT1A receptor
and enhanced anandamide signalling) [99]. Due to this,
studies have primarily employed isolated CBD, however
this work could potentially be extended to formulas
from whole-plant strains which are high in CBD (> 10
mg/g) and lower in THC (< 4mg/g). These preparations
may also contain other yet-to-be-studied compounds
from the plant which may be beneficial for the positive
or negative symptoms of schizophrenia.
In respect to current research, aside from an initial
index case study conducted by Zuardi, Morais [100] in
1995, who showed that 1500mg of CBD administered for
26 days was beneficial for treatment-resistant schizophre-
nia, three clinical studies exist to date. A study by Leweke,
Piomelli [99] tested in a double-blind, RCT design 600–
800mg/day of oral CBD vs the antipsychotic amisulpride
over 4 weeks in 42 patients. While both treatments were
safe and led to significant non-differential clinical im-
provements, the CBD arm had a superior side-effect pro-
file. CBD also significantly increased anandamide levels,
which was associated with clinical improvement. Another
double-blind parallel-group trial, involving 88 patients
with schizophrenia who were given either oral CBD (1000
mg/day) or placebo adjunctively to existing antipsychotic
medication revealed after 6 weeks of treatment that the
CBD group had lower levels of positive psychotic symp-
toms on the Positive and Negative Syndrome Scale
(PANSS), and were more likely to have been rated as im-
proved via clinician-ratings [101]. While these studies
were supportive of CBD, a recent double-blind RCT by
Boggs, Surti [102] found no benefit for 600mg/day of
CBD in comparison to placebo. The 6-week study involv-
ing 36 patients with schizophrenia revealed that both pla-
cebo and CBD PANSS scores improved, but no Group ×
Time effect was evident. The CBD was well-tolerated,
however, and more sedation was evident in the CBD
group compared to placebo.
Furthermore, CBD may confer some protective effects
in young people at clinical high-risk for psychosis (n = 33),
as a recent single-dose RCT found that 600mg of CBD
temporarily normalised aberrant brain activity in the para-
hippocampal, striatal, and midbrain areas, which is associ-
ated with increased psychosis risk [103]. Currently, an
ongoing clinical trial in the United Kingdom is assessing
the efficacy of 600mg of CBD per day for reducing symp-
toms of psychosis in young people at clinical high-risk for
psychosis [104].
Bipolar disorder
To date no clinical trial has assessed cannabinoids for the
treatment of bipolar disorder (in respect to maintaining
euthymia, or as a treatment of hypo/mania or depression),
although there is a potential role of the endocannabinoid
system in the disorder, as detailed above. Initial case re-
ports contend this approach may not however be of bene-
fit [105]. Two patients diagnosed with DSM-IV Bipolar
type I disorder, and presenting with mania, were provided
adjunctive CBD (titrated to 1200mg per day) after receiv-
ing placebo for an initial five-day period. On Day 31, CBD
treatment was discontinued and replaced by placebo for
five days. While the first patient showed symptom im-
provement while on olanzapine plus CBD, she showed no
additional improvement during CBD monotherapy, while
the second patient had no symptom improvement with
any dose of CBD during the trial. Both patients tolerated
CBD very well and no side-effects were reported, despite
no obvious effect on reducing mania.
ADHD
Evidence has revealed that adults with ADHD may self-
medicate with cannabis as a coping strategy for a range of
potential effects [106]. Off-label use in the US for this ap-
plication has been noted despite a relative deficit of evi-
dence for this use [107]. One study was located, the
“Experimental Medicine in ADHD-Cannabinoids” pilot
RCT, using nabiximol (cannabinoid/terpene combination)
oromucosal spray in 30 adults with ADHD for 6 weeks
[108]. The primary outcome was cognitive performance
and activity level (as measured by head movements) using
the Quantitative Behavioural Test. Secondary outcomes
included ADHD and emotional lability symptoms. While
a trend towards significance occurred in favour of nabixi-
mols, no significant difference was revealed on the pri-
mary outcomes. Notably, the use of nabiximols did not
impair cognition. For secondary outcomes, the combin-
ation of note was associated with a nominally significant
improvement in hyperactivity/impulsivity scores on the
investigator-rated Conners Adult ADHD Rating Scale.
The combination was well-tolerated, however, a serious
adverse event involving muscular seizures/spasms oc-
curred in the active group. While not definitive, this study
provides preliminary evidence supporting the self-
medication theory of cannabis use in ADHD and the need
for further studies of the endocannabinoid system in
ADHD. Results, however, did not meet significance fol-
lowing adjustment for multiple testing, and it should be
recognised that the sample size was small, thus a more
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robust sample would be better placed to determine the
true effect.
Discussion
Data synthesis
As the present data indicates, the current field of canna-
binoid therapeutics in psychiatry currently provides no
convincing evidentiary support for use in any mental
health application. More research is urgently needed,
and many RCTs are currently being undertaken; thereby
the landscape will change rapidly over the next several
years. Currently, the most promising (although inconclu-
sive) evidence is for CBD as an adjunctive treatment in
schizophrenia, with an additional isolated study showing
efficacy in social anxiety, and weak data suggesting a po-
tential effect for ADHD symptoms. The evidence also
tentatively suggests that a role exists for cannabinoids in
PTSD, and also in reducing insomnia, which may also
commonly occur in chronic pain. For other plant-
derived cannabinoid therapy applications for psychiatric
symptoms/disorders (e.g. several affective disorders) no
firm conclusions can currently be drawn.
Clinical prescriptive considerations
It initially should be recognised by clinicians that, as
detailed above, weak evidence currently exists in the
field, thus this prescriptive advice should be taken in
the context of evolving research. The first consider-
ation faced by a clinician (in a legal jurisdiction) with
a patient who is interested (or for clinician-initiated
prescription) in using cannabis medicinally, is whether
this is medically appropriate for them. A thorough
screening firstly needs to occur, with Canadian British
Columbian Physician guidelines [109] suggesting that
clinicians initially assess:
 Age – higher-dose THC forms not advised in people
< 25 years of age;
 If a personal history or family history of psychosis is
present, and if so, no THC is advised;
 Any current or past drug or alcohol misuse or
dependence (avoid especially in individuals with
cannabis dependence or misuse);
 Cardiovascular or respiratory diseases (avoid or use
caution);
 Current medications which may interact with
cannabis; and
 Pregnant or planning or conceive or breastfeeding
(avoid).
Next, if no contraindication is apparent, medical con-
sideration can be given to what potential clinical applica-
tion the MC may present for, and the cannabis
formulation or isolate/s that may be appropriate for
them. Given the complexity of MC whole-plant formulas
(and the current challenge to standardise for batch-to-
batch consistency), companies have primarily tested can-
nabinoid isolates and analogues. The most studied
including nabiximols (Sativex), nabilone (Cesamet), and
dronabinol (Marinol). While this may provide more
pharmacological assurity, such an approach also negates
the potential of unique genetic chemovars of cannabis
which may provide specific therapeutic activity due to a
complex synergistic interaction of constituents (known
as the entourage effect). Patient preference may also be
towards vaporisation of dried raw material [110]. To this
end, specific prescriptive considerations need to be
adopted, including:
 Determining patient preference regarding
administration - vaporisation (via specific devices),
inhalation via traditional smoking apparatuses, oral
dose (i.e. capsule, oil or in some cases food product),
sublingual via lozenges or sprays. Note that each has
a different onset of action and half-life. Inhalants will
provide a more instantaneous effect (due to the alac-
rity of THC decarboxylation), whereas oral forms
will take longer e.g. 45–90 min to take effect. Both
forms of administration may be advisable to provide
flexible symptom management;
 Patient’s personality in terms of the effects of higher
THC formulas. Avoidance of higher THC formulas
should occur in youth and in those with paranoid
personalities;
 Potential for abuse (with greater theoretical
potential in vaporised/inhaled forms [which also
carries additional general health consequences]);
 When the application should occur with respect to
occupational and carer responsibilities and driving.
Note that there is the potential to prescribe
different cannabis preparations which contain
differing levels of THC and CBD, with higher
dose THC applications being applied preferentially
in the evening.
 CBD dosage (based on current evidence) varies
according to disorder, age, weight, and potentially
pharmacogenetic differences. Most research tends to
focus on a range of 200 mg–800 mg per day [111].
In respect to THC-containing formulas, it has been
advised to be cautious exceeding 20 mg per day due
to potential side effects [112], and people may find a
psychotropic effect with as little as 1 mg–2.5 mg per
dose.
As mentioned above, there are a myriad of potential
cannabis chemovars that can be developed, each with
unique medicinal applications. However, to maintain
pharmacodynamic/kinetic consistency, at present, the
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two major constituents commonly standardised for are
THC and CBD (in some cases select terpenes are also
included). THC provides, as indicated above, the primary
psychotropic effect, and higher doses may be preferable
for the amelioration of pain and inducement of sleep
[63]. Further, it may provide an acute mood elevating ef-
fect in some people, however as mentioned, this may
also elicit symptoms of paranoia, anxiety, and cognitive
impairment (and in higher doses may actually impair
mood). This effect may potentially be opposed by CBD
(and/or other less studied cannabinoids), however data
is mixed as to this effect. Additionally, the findings are
not clear cut, with users of cannabis (to treat anxiety)
having a statistically significant preference for higher
THC/lower CBD containing cannabis cultivars [113].
Safety considerations
Clinicians needs to be aware that cannabinoid therapies
may elicit a range of side effects. In respect to potentially
expected side-effects from cannabinoid interventions,
occasional adverse effects revealed in clinical trials in-
clude co-ordination problems, dizziness, disorientation,
euphoria, drowsiness or fatigue, dry mouth, nausea and
gastrointestinal upsets [10]. Due to this, regular monitor-
ing is advised, especially when commencing treatment in
cannabis-naïve patients.
The previously cited report conducted by the National
Academy of Sciences [6] on the health effects of canna-
bis and cannabinoids cites limited evidence that canna-
bis use increases the rates of initiation of other
psychoactive drugs. Additionally, while there are con-
cerns over the relationship with schizophrenia, no firm
evidence shows any association between cannabis use
and the likelihood of developing bipolar disorder. Fur-
ther evidence is suggestive that smoking cannabis on a
regular basis is associated with cough and phlegm pro-
duction, while limited evidence exists suggestive of a
statistical association between cannabis use and ischae-
mic stroke and/or acute myocardial infarction. Evidence
is noted to exist for the association between increased
cannabis use frequency and progression to developing
problematic cannabis use [6], as well as potential re-
spiratory infections/disorders (especially in the use of
poor-quality raw material). Clinicians need to balance
these concerns together with the potential benefits, espe-
cially regarding the potential for lesser harm from other
prescriptive or illicit options in patients managing psy-
chiatric and pain conditions.
Pharmacogenetic considerations
Increased attention to the influence of pharmacogenetics
factors is advised, with several genes being identified that
may differentially affect cannabinoid pharmacokinetics and
pharmacodynamics. A recent review led by Hryhorowicz
[114] characterised pertinent genes with relevant inter-
action with cannabis into three broad categories: Receptor
genes (CNR1, CNR2, TRPV1, and GPR55), transporter
genes (ABCB1, ABCG2, SLC6A) and pharmacokinetic/me-
tabolism (CYP3A4, CYP2C19, CYP2C9, CYP2A6, CYP1A1,
COMT, FAAH, COX2, ABHD6, ABHD12). Research into
the pharmacogenomic influence is however nascent, with
most of the focus being on the relationship with cannabis
dependence (e.g. CNR1 receptor SNPs which shows no ob-
vious association), or schizophrenia (COMT, DRD2 SNPs
showing a stronger correlation) [81, 114]. Further explor-
ation of FAAH SNPs differentially affecting people’s re-
sponse to CBD is also of value (given its important role in
inhibiting the degradation of anandamide).
Occupational and public health considerations
Occupational health and safety issues also exist in con-
sideration with medicinal cannabis users. Workplace
safety concerns have been raised in relation to the po-
tential for medicinal cannabis use to impair judgement
and psychomotor skills, especially in relation to motor
vehicle use, operation of fixed and mobile plants particu-
larly heavy industrial machinery, and the potential for
risk-taking behaviors and those working in safety sensi-
tive positions [115, 116]. Employers have a ‘duty of care’
to provide safe and healthy workplaces, which includes
the management of alcohol and drug use and their po-
tential to create unsafe workplaces or practices. Work-
place drug testing (WDT) is common in some industries
including mining, transportation and correctional ser-
vices [117]. Employees in building, transportation, mari-
time and mining operations cannot use drugs, legal or
illegal, if they could impair their ability to safely under-
take their duties [118]. However, the presence of a drug,
or its metabolite, in a person’s system is not always pro-
portional to cognitive impairment [119]. In addition,
WDT does not discriminate between recreational or me-
dicinal use and could place medicinal cannabis patients
at risk of discrimination or unfair dismissal. Implemen-
tation of WDT should be balanced with a greater know-
ledge on the dose response relationship between
cannabis-based medicines and their potential side
effects.
Medicinal cannabis patients may also be subject to
mobile drug testing in jurisdictions such as Australia.
The salivary testing process is inefficient for assessment
of cannabis related driving impairment because the tests
can trace THC in saliva for days after consumption, long
after any cognitive impairment has abated. The potential
impact of medicinal cannabis on function will vary with
dose, the length of usage (tolerance), route of adminis-
tration (oral versus smoking), [120] and saliva THC
levels are not direct measures of cognitive status. Fur-
ther, the concentration of THC in urine does not
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correlate with cognitive function [120]. Conversely, in
the US, a whole blood THC level of 5 ng/mL has been
established as a legal limit for driving in states where
cannabis has been legalised [121]. Guidelines and strat-
egies for the specific risk management of cannabis in the
workplace have been published in North America [120–
123]. However, Australia is yet to publish its own risk
management guidelines relating to medicinal cannabis in
the workplace, although generic workplace alcohol and
drug risk management guidelines could be adapted in
the interim [118].
Future research considerations
It should also be noted that the majority of studies assessing
the effect of cannabis on cognitive function were under-
taken with low potency THC strains (< 4% THC), [120]
and further study is required for both high potency THC
medicines, as well as THC-free medicines such as CBD
[121]. Further, more research is needed on the dosage re-
quired (especially of CBD and lesser studied cannabinoids),
the potential entourage effect, the pharmacokinetics, and
the influence of pharmacogenetics on both metabolism of
the cannabinoids and the pharmacodynamics. Novel trial
designs are advised in some instances, particularly involving
employing high-quality RCTs (or N-of-1 designs), to ex-
plore the potential benefits in psychiatric conditions.
While research is rapidly advancing, there is a chal-
lenge regarding the adequate blinding of medicinal can-
nabis studies (due to the obvious psychotropic effect,
and lack thereof in cannabinoid-removed controls)
[124]. This may be addressed via cannabis naïve partici-
pants with psychomimetic controls (e.g. atropine; these
however have the innate challenges of being biologically
active themselves); adequate assessment of un/blinding;
and use of varying levels of THC within the study. It still
should, however, be taken in the context of other psychi-
atric or neurological research, with opioids and benzodi-
azepines also eliciting an obvious psychophysiological
effect, and the acceptance of the research demonstrating
analgesic and anxiolytic effects, respectively.
Conclusions
Currently the evidence is nascent and too weak to rec-
ommend cannabinoid-based interventions for a range of
psychiatric disorders. While encouraging, research is
only just beginning to determine whether cannabis or its
isolates may or may not be effective for this application,
and clinicians need to be mindful of several safety consider-
ations (as articulated above). The most promising (although
inconclusive) evidence is for CBD as an adjunctive treat-
ment in schizophrenia, with an additional isolated study
showing efficacy in social anxiety, and some data suggesting
a potential effect for PTSD and ADHD symptoms. The data
also tentatively suggests that a role exists for cannabinoids
in reducing insomnia, which may also commonly occur in
chronic pain. Given the generally favorable safety profile of
cannabinoids observed across the observational studies and
clinical trials conducted to date, there is clearly a strong
case for encouraging further research.
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